MDMA Therapy For PTSD Closer To Legality As Key FDA Approval Meeting Approaches, Sparking Hope And Controversy

MDMA, the drug commonly known as ecstasy and declared illegal by the DEA in 1985, is nearing a landmark moment in its journey toward becoming a legal and approved treatment for PTSD. Lykos Therapeutics Inc., a company that emerged from the nonprofit Multidisciplinary Association for Psychedelic Studies (MAPS), has spearheaded this effort, bringing the first new PTSD treatment in over two decades to the brink of FDA approval.

FDA Review And Potential Approval Timeline

On Tuesday, the FDA’s Psychopharmacologic Drugs Advisory Committee will meet to discuss the drug application submitted by Lykos, providing the first clear indication of the FDA’s stance on this treatment and possibly paving the way for a final decision by August. According to Bloomberg, the treatment involves administering MDMA in conjunction with 42 hours of therapy, a method aimed at addressing the deep-seated trauma experienced by PTSD patients which has shown promising results …

Full story available on Benzinga.com